{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036816","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.942957+00:00","generated_at":"2026-06-04T07:01:49.130816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026","bullets":["FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.","Cash $116.7M at Dec 31, 2023; recent $40M public offering and CAR T licensing deals add ~$50M.","Completed licensing deals with Imugene, TG Therapeutics, and Caribou; total upfront/near-term ~$50M.","PBGENE-HBV IND/CTA submission planned in 2024; PBGENE-PMM submission in 2025.","Net loss per diluted share $(15.96) vs $(38.10) in FY 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036816","json":"https://secwatch.observer/filing/0000950170-24-036816.json","markdown":"https://secwatch.observer/filing/0000950170-24-036816.md","text":"https://secwatch.observer/filing/0000950170-24-036816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/0000950170-24-036816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/dtil-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:01:49.130816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ce0eeca27f5525ef1de806bf25f1ab12f76c38b3","claim":"PRECISION BIOSCIENCES INC reported financial results for quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024036816/0000950170-24-036816-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}